AGIO · Agios Pharmaceuticals, Inc.
$33.60
-0.12% last session
End-of-day data · close of 2026-09-11
Market cap
$2B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-8.5
Dividend yield
—
Beta
0.60
Avg volume
1M
Employees
1K
Daily Change %
-0.12%
5 Days Change
4.62%
10 Days Change
2.82%
30 Days Change
5.93%
60 Days Change
-16.01%
Month to Day Change
1.23%
Year to Day Change
27.22%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — AGIO
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-07
Latest call per bank · past 12 months
JP Morgan
Neutral$34.00
+1.1% vs priceCitigroup
Buy$52.00
+54.6% vs priceRBC Capital
Sector Perform$32.00
-4.9% vs priceBank of America
Buy$46.00
+36.7% vs priceGoldman Sachs
Neutral$32.00
-4.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-07 | JP Morgan | Maintains | Neutral | $31.00 → $34.00 |
| 2026-07-31 | Citigroup | Maintains | Buy | $46.00 → $52.00 |
| 2026-07-31 | Truist Securities | Maintains | Buy | $41.00 → $39.00 |
| 2026-07-30 | HC Wainwright & Co. | Maintains | Buy | $52.00 → $55.00 |
| 2026-07-21 | HC Wainwright & Co. | Maintains | Buy | $54.00 → $52.00 |
| 2026-07-07 | RBC Capital | Maintains | Sector Perform | $28.00 → $32.00 |
| 2026-07-07 | Truist Securities | Maintains | Buy | $36.00 → $41.00 |
| 2026-07-07 | Bank of America | Maintains | Buy | $40.00 → $46.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 48 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 5.0% below the 50-day MA ($35.35).
- Price vs 200-day MA: Trading 9.8% above the 200-day MA ($30.59).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.08) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($22.34) and high ($45.49).
AGIO Price Chart
Loading chart for AGIO…
Fundamentals
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.